Profile | GDS2987 / Hs.479325-S |
Title | Comparison of Rho kinase inhibitor and atorvastatin effects on primary cell lines |
Organism | Homo sapiens |
Sample | Title | Value | Rank |
---|---|---|---|
GSM214810 | HMVEC_vehicle_rep1 | 0.4 | 1 |
GSM215244 | HMVEC_vehicle_rep2 | 9.9 | 26 |
GSM215253 | HMVEC_vehicle_rep3 | ||
GSM215254 | HMVEC_atorvastatin_rep1 | ||
GSM215282 | HMVEC_atorvastatin_rep3 | 2 | 5 |
GSM215344 | HMVEC_atorvastatin_rep2 | 1.2 | 3 |
GSM215283 | HMVEC_atorvastatin_mevalonate_rep1 | ||
GSM215284 | HMVEC_atorvastatin_mevalonate_rep2 | 5.4 | 11 |
GSM215293 | HMVEC_atorvastatin_mevalonate_rep3 | ||
GSM215294 | HMVEC_SLx2119_rep1 | ||
GSM215295 | HMVEC_SLx2119_rep2 | ||
GSM215296 | HMVEC_SLx2119_rep3 | ||
GSM215297 | PASMC_vehicle_rep1 | 14.5 | 23 |
GSM215298 | PASMC_vehicle_rep2 | 21.5 | 32 |
GSM215310 | PASMC_vehicle_rep3 | ||
GSM215311 | PASMC_atorvastatin_rep1 | 30.8 | 48 |
GSM215312 | PASMC_atorvastatin_rep2 | ||
GSM215313 | PASMC_atorvastatin_rep3 | 1.2 | 2 |
GSM215324 | PASMC_atorvastatin_mevalonate_rep1 | 3 | 5 |
GSM215325 | PASMC_atorvastatin_mevalonate_rep2 | ||
GSM215326 | PASMC_atorvastatin_mevalonate_rep3 | ||
GSM215327 | PASMC_SLx2119_rep1 | ||
GSM215328 | PASMC_SLx2119_rep2 | 5.1 | 10 |
GSM215329 | PASMC_SLx2119_rep3 | 1.8 | 3 |
GSM215330 | Fibroblasts_vehicle_rep1 | 21.3 | 44 |
GSM215331 | Fibroblasts_vehicle_rep2 | ||
GSM215332 | Fibroblasts_vehicle_rep3 | ||
GSM215333 | Fibroblasts_atorvastatin_rep1 | 17.2 | 42 |
GSM215334 | Fibroblasts_atorvastatin_rep2 | ||
GSM215335 | Fibroblasts_atorvastatin_rep3 | ||
GSM215336 | Fibroblasts_atorvastatin_mevalonate_rep1 | ||
GSM215337 | Fibroblasts_atorvastatin_mevalonate_rep2 | ||
GSM215338 | Fibroblasts_atorvastatin_mevalonate_rep3 | 3.3 | 10 |
GSM215339 | Fibroblasts_SLx2119_rep1 | ||
GSM215340 | Fibroblasts_SLx2119_rep2 | ||
GSM215341 | Fibroblasts_SLx2119_rep3 | 3.8 | 10 |